Enanta Pharmaceuticals (NASDAQ: ENTA) net income
Enanta Pharmaceuticals reported a net loss of $81.9m for fiscal 2025; in fiscal 2024 it reported a net loss of $116.0m. Earnings per share were −$3.84.
Enanta Pharmaceuticals's best year of the last 10 was fiscal 2018. The biggest drop was in fiscal 2019, −35.5%. It reported a loss in 6 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$81.9m | — | −125.4% | −$3.84 |
| 2024 | −$116.0m | — | −171.6% | −$5.48 |
| 2023 | −$133.8m | — | −169.0% | −$6.38 |
| 2022 | −$121.8m | — | −141.3% | −$5.91 |
| 2021 | −$79.0m | — | −81.4% | −$3.92 |
| 2020 | −$36.2m | −178.0% | −29.5% | −$1.81 |
| 2019 | $46.4m | −35.5% | 22.6% | $2.37 |
| 2018 | $72.0m | +306.3% | 34.8% | $3.74 |
| 2017 | $17.7m | −18.3% | 17.2% | $0.93 |
| 2016 | $21.7m | — | 24.5% | $1.14 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Enanta Pharmaceuticals net income compared with its sector
By net income for its latest fiscal year, Enanta Pharmaceuticals ranks 319th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Enanta Pharmaceuticals, −125.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 317th | Zymeworks | −$81.1m | −76.6% |
| 318th | Personalis | −$81.3m | −116.7% |
| 319th | Enanta Pharmaceuticals | −$81.9m | −125.4% |
| 320th | LENZ Therapeutics | −$82.1m | −430.3% |
| 321st | Geron | −$83.5m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Enanta Pharmaceuticals
- How much did Enanta Pharmaceuticals earn in fiscal 2025?
- Enanta Pharmaceuticals reported a net loss of $81.9m for fiscal 2025. In fiscal 2024 it reported a net loss of $116.0m.
- What are the earnings per share of Enanta Pharmaceuticals?
- They were −$3.84 in fiscal 2025, compared with −$5.48 in fiscal 2024.
- What was the most profitable year for Enanta Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2018, with $72.0m.
- Where does Enanta Pharmaceuticals rank in its sector by net income?
- It ranks 319th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Enanta Pharmaceuticals come from?
- From the annual report (Form 10-K) that Enanta Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Enanta Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Enanta Pharmaceuticals: the Enanta Pharmaceuticals page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.